Systemic review and meta-analysis of the three-component drug regimen (alpha-glutamyl-tryptophan, bendazole, ascorbic acid) prophylactic efficacy

Authors:

Смирнов В.С.,

Петленко С.В.,

Краснов А.А.,

Апрятина В.А.,

Заплутанов В.А.,

Скрипачева Я.Ю.

Журнал: Профилактическая медицина. 2025;28(8):48-55.

DOI: 10.17116/profmed20252808148

Read: 2307 раз

Download PDF (RU)Download PDF (EN)

Abstract

Influenza and acute respiratory viral infections (ARVI) have a high prevalence, which determines their clinical and economic relevance. Agents activating nonspecific antiviral immunity mechanisms can be used to prevent these infections.

OBJECTIVE

To perform a systematic review and meta-analysis of the results of clinical studies on the preventive antiviral effectiveness of the three-drug regimen (alpha-glutamyl-tryptophan, bendazole, and ascorbic acid) against influenza and acute respiratory viral infections.

MATERIALS AND METHODS

Following the PRISMA guidelines, the results of controlled clinical studies on the preventive effectiveness of the three-drug regimen (alpha-glutamyl-tryptophan, bendazole, and ascorbic acid) were selected using the recommended databases. The effectiveness was evaluated based on serum levels of total and stimulated interferon, serum and salivary immunoglobulin A levels, and oxidative and phagocytic activity of granulocytes and monocytes. The risk of bias and the quality of studies were assessed using the RoB 2 tool. The meta-analysis was conducted using the Meta package of the R statistical software and included an assessment of the generalized differences in the mean values of the parameters before and after the treatment course (Z-test), an assessment of the fixed/random weight of the studies, and verification of their heterogeneity (I² test).

RESULTS

The results of four clinical studies, published between 2018 and 2021, were selected. A statistically significant (generalized) treatment effect size was identified for induced oxidative activity of granulocytes (an increase of 2.18 standard deviations; p=0.0004; I²=87.2%); salivary IgA levels (an increase of 0.73 standard deviations; p=0.0001; I²=86.6%); phagocytic activity of monocytes (an increase of 1.39 standard deviations; p=0.0001; I²=90.9%); phagocytic activity of granulocytes (an increase of 0.85 standard deviations; p=0.0031; I²=82.7%).

CONCLUSION

The studied treatment regimen demonstrated an adaptive-activating effect on various elements of innate antigen-nonspecific immunity, contributing to the prevention of influenza and acute respiratory viral infections.

Keywords

prevention of infectious diseases
meta-analysis

Дата поступления: 05.08.2025

Дата принятия в печать: 12.08.2025

Дата публикации: 27.08.2025

References

Danny`e statistiki Rospotrebnadzora. E`lektronny`j resurs. Accessed July 07, 2025. (In Russ.). https://rospotrebnadzor.ru/activities/statistical-materials/statictic_details.php?ELEMENT_ID=11277
Smirnov VS, Petlenko SV. Gripp i ostry`e respiratorny`e virusny`e infekcii (xarakteristika, patogenez, profilaktika i lechenie). 3-e izd., pererab. i dop. SPb.: Gippokrat; 2019. (In Russ.).
Lebedev KA, Ponyakina ID. Immunogramma v klinicheskoj praktike. M.: Nauka; 1990. (In Russ.).
Novikov DK, Novikova VI. Ocenka immunnogo statusa. M.: Vitebskij medinstitut; 1996. (In Russ.).
Cochrane Collaboration. Cochrane handbook for Systematic Reviews of Interventions. Accessed July 07, 2025. https://www.cochranehandbook.org
Moher D, liberati A, Tetzla J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Medicine. 2009;3(3):e123-e130.
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928
DerSimonian R, laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986;7(3):177-188.
Golovacheva EG, Afanasieva OI, Popova VV, et al. Study concerning immune system parameters in the prevention of acute respiratory viral infections using a drug with antiviral and immunotropic activity in healthy subjects. RMJ. 2021;4:17-21. (In Russ.).
Ruleva AA, Popova VV, Lyovina AV, et al. Immunological mechanisms of the drug Cytovir®-3 action as the basis of the prevention of acute respiratory viral infections and infl uenza. Immunologiya. 2021;42(2):148-158. (In Russ.). https://doi.org/10.33029/0206-4952-2021-42-2-148-158
CzPK-2015/IV «Otkry`toe, sravnitel`noe, randomizirovannoe issledovanie v parallel`ny`x gruppax e`ffektivnosti i bezopasnosti preparatov «Citovir®-3», kapsuly` (ZAO «MBNPK «Citomed», Rossiya) i «Arbidol®», kapsuly` 100 mg («Farmstandart Leksredstva», Rossiya) pri profilaktike grippa i ORVI u detej». https://grlsbase.ru/clinicaltrails/clintrail/2473
RSCz/2017 «Otkry`toe issledovanie bezopasnosti i perenosimosti preparata «Citovir®-3», kapsuly` u zdorovy`x dobrovol`cev. Accessed July 07, 2025. (In Russ.). https://grlsbase.ru/clinicaltrails/clintrail/1210
CzP/2018 «Otkry`toe issledovanie bezopasnosti i perenosimosti preparata «Citovir®-3», poroshok dlya prigotovleniya rastvora dlya priyoma vnutr` [dlya detej] [bez aromatizatorov, apel`sinovy`j, klubnichny`j, klyukvenny`j], u zdorovy`x dobrovol`cev». Accessed July 07, 2025. (In Russ.). https://grlsbase.ru/clinicaltrails/clintrail/879
CzS/2018 «Otkry`toe issledovanie bezopasnosti i perenosimosti preparata «Citovir®-3», sirop [dlya detej], u zdorovy`x dobrovol`cev». Accessed July 07, 2025. (In Russ.). https://grlsbase.ru/clinicaltrails/clintrail/818